BICO Group AB
STO:BICO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
34.02
69.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
BICO Group AB
BICO Group AB
Cash & Cash Equivalents
BICO Group AB
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BICO Group AB
STO:BICO
|
Cash & Cash Equivalents
kr861m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
AddLife AB
STO:ALIF B
|
Cash & Cash Equivalents
kr272m
|
CAGR 3-Years
8%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Biotage AB
STO:BIOT
|
Cash & Cash Equivalents
kr370m
|
CAGR 3-Years
1%
|
CAGR 5-Years
23%
|
CAGR 10-Years
17%
|
|
|
G
|
Genovis AB
STO:GENO
|
Cash & Cash Equivalents
kr135.8m
|
CAGR 3-Years
48%
|
CAGR 5-Years
72%
|
CAGR 10-Years
41%
|
|
|
MedCap AB (publ)
STO:MCAP
|
Cash & Cash Equivalents
kr287.7m
|
CAGR 3-Years
29%
|
CAGR 5-Years
76%
|
CAGR 10-Years
15%
|
|
|
M
|
Magle Chemoswed Holding AB
STO:MAGLE
|
Cash & Cash Equivalents
kr7.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
BICO Group AB
Glance View
BICO Group AB is a bioconvergence company, which engages in the provision of technologies, products, and services to create, understand and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 890 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
See Also
What is BICO Group AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
861m
SEK
Based on the financial report for Dec 31, 2023, BICO Group AB's Cash & Cash Equivalents amounts to 861m SEK.
What is BICO Group AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
26%
Over the last year, the Cash & Cash Equivalents growth was -7%. The average annual Cash & Cash Equivalents growth rates for BICO Group AB have been 26% over the past three years .
You don't have any saved screeners yet
